Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.58
LXRX's Cash to Debt is ranked higher than
66% of the 891 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. LXRX: 4.58 )
LXRX' s 10-Year Cash to Debt Range
Min: 1.31   Max: No Debt
Current: 4.58

Equity to Asset 0.58
LXRX's Equity to Asset is ranked higher than
65% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. LXRX: 0.58 )
LXRX' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.96
Current: 0.58

0.33
0.96
F-Score: 2
Z-Score: -1.96
M-Score: -2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4607.16
LXRX's Operating margin (%) is ranked higher than
52% of the 753 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. LXRX: -4607.16 )
LXRX' s 10-Year Operating margin (%) Range
Min: -9955.46   Max: -47.73
Current: -4607.16

-9955.46
-47.73
Net-margin (%) -4686.14
LXRX's Net-margin (%) is ranked higher than
52% of the 753 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. LXRX: -4686.14 )
LXRX' s 10-Year Net-margin (%) Range
Min: -10120.39   Max: -47.98
Current: -4686.14

-10120.39
-47.98
ROE (%) -61.19
LXRX's ROE (%) is ranked higher than
60% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. LXRX: -61.19 )
LXRX' s 10-Year ROE (%) Range
Min: -154.05   Max: -12.52
Current: -61.19

-154.05
-12.52
ROA (%) -37.98
LXRX's ROA (%) is ranked higher than
65% of the 852 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. LXRX: -37.98 )
LXRX' s 10-Year ROA (%) Range
Min: -56.07   Max: -11.78
Current: -37.98

-56.07
-11.78
ROC (Joel Greenblatt) (%) -247.50
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -214.14 vs. LXRX: -247.50 )
LXRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -254.29   Max: -42.36
Current: -247.5

-254.29
-42.36
Revenue Growth (%) -100.00
LXRX's Revenue Growth (%) is ranked higher than
52% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. LXRX: -100.00 )
LXRX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 52.2
Current: -100

-100
52.2
EBITDA Growth (%) -15.10
LXRX's EBITDA Growth (%) is ranked higher than
70% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. LXRX: -15.10 )
LXRX' s 10-Year EBITDA Growth (%) Range
Min: -28.7   Max: 22.6
Current: -15.1

-28.7
22.6
EPS Growth (%) -16.20
LXRX's EPS Growth (%) is ranked higher than
72% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. LXRX: -16.20 )
LXRX' s 10-Year EPS Growth (%) Range
Min: -26.1   Max: 30.8
Current: -16.2

-26.1
30.8
» LXRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

LXRX Guru Trades in Q2 2013

Chuck Royce 4,393,933 sh (unchged)
Mario Gabelli 143,200 sh (unchged)
Steven Cohen Sold Out
» More
Q3 2013

LXRX Guru Trades in Q3 2013

Chuck Royce 4,393,933 sh (unchged)
Mario Gabelli 143,200 sh (unchged)
» More
Q4 2013

LXRX Guru Trades in Q4 2013

Jim Simons 246,345 sh (New)
Paul Tudor Jones 31,370 sh (New)
Steven Cohen 27,794 sh (New)
Louis Moore Bacon 150,000 sh (New)
Mario Gabelli 143,200 sh (unchged)
Chuck Royce 4,233,933 sh (-3.64%)
» More
Q1 2014

LXRX Guru Trades in Q1 2014

Mario Gabelli 143,200 sh (unchged)
Chuck Royce 4,233,933 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Paul Tudor Jones 24,640 sh (-21.45%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2012-12-31 Add 509.52%$1.6 - $2.69 $ 1.67-16%128000
Mario Gabelli 2012-09-30 New Buy$2.12 - $3.18 $ 1.67-32%21000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.20
LXRX's P/B is ranked higher than
71% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 5.83 vs. LXRX: 6.20 )
LXRX' s 10-Year P/B Range
Min: 0.51   Max: 6.3
Current: 6.2

0.51
6.3
P/S 400.00
LXRX's P/S is ranked lower than
51% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. LXRX: 400.00 )
LXRX' s 10-Year P/S Range
Min: 0   Max: 400
Current: 400

0
400
EV-to-EBIT 30.30
LXRX's EV-to-EBIT is ranked higher than
60% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LXRX: 30.30 )
LXRX' s 10-Year EV-to-EBIT Range
Min: 30.2   Max: 37.3
Current: 30.3

30.2
37.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.90
LXRX's Price/Tangible Book is ranked higher than
62% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. LXRX: 20.90 )
LXRX' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 21.63
Current: 20.9

0.89
21.63
Price/Median PS Value 3.10
LXRX's Price/Median PS Value is ranked higher than
63% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 1.99 vs. LXRX: 3.10 )
LXRX' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 18
Current: 3.1

0.07
18
Forward Rate of Return (Yacktman) -39.87
LXRX's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -9.71 vs. LXRX: -39.87 )
LXRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.7   Max: -29.2
Current: -39.87

-31.7
-29.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LX3.Germany
Lexicon Pharmaceuticals, Inc. was incorporated in Delaware in July 1995, and commenced operations in September 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. It has multiple drug programs in various stages of clinical development: It has completed a Phase 2a clinical trial and are presently conducting a Phase 2b clinical trial of LX4211; It has completed a Phase 2 clinical trial and are presently conducting an additional Phase 2 clinical trial and preparing for the initiation of pivotal Phase 3 clinical trials of LX1032; The Company presently conducting a Phase 2 clinical trial of LX1033; It has completed a Phase 2a clinical trial and are presently conducting a dose-ranging study to explore higher doses of LX2931; It is presently conducting a Phase 1 clinical trial of LX7101, a topically-delivered small molecule compound that it is developing as a treatment for glaucoma. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide